Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Satisfactorily completion of HMR1726D/2001 study with respect to safety.~* If female subject, non-childbearing potential or child bearing potential with adequate contraception.~* Consent to practice/maintain adequate means of contraception throughout the study and for 24 months after the discontinuation of treatment.~* Clinically definite Multiple Sclerosis (MS) as established on entry into HMR1726D/2001 study.~* Extended Disability Status Score(EDSS) between 0 and 6 inclusively, when the subject entered HMR1726D/2001 study.~* Magnetic Resonance Imaging (MRI) criteria must continue to support the diagnosis of clinically definite MS.~* Willingness to participate in a long-term safety and efficacy trial.~Exclusion Criteria:~* Subject who did not complete HMR 1726D/2001 study for safety reasons.~* Subject who developed clinically relevant cardiovascular, hepatic, endocrine or other major disease.~* Pregnancy.~* Breast-feeding.~* Wish to parent.~* Likelihood of requiring treatment during the study period with drugs not permitted.~* Disallowed therapies such asw immunomodulators, immunosuppressants.~* Recent history of drug or alcohol abuse.~* Liver function impairment.~* Abnormal mental conditions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Teriflunomide 7 mg (Type: EXPERIMENTAL): None
- Teriflunomide 14 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).